Holen Sie sich die Stockscreener-App
14.12
2.54%
0.35
Handel nachbörslich:
14.12
Schlusskurs vom Vortag:
$13.77
Offen:
$13.86
24-Stunden-Volumen:
1.11M
Relative Volume:
1.23
Marktkapitalisierung:
$898.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-129.61M
KGV:
-4.727
EPS:
-2.9871
Netto-Cashflow:
$-116.59M
1W Leistung:
-2.08%
1M Leistung:
-34.02%
6M Leistung:
-8.84%
1J Leistung:
+69.51%
1-Tages-Spanne:
$13.31
$14.17
1-Wochen-Bereich:
$13.31
$14.74
52-Wochen-Spanne:
$8.20
$28.00
Jade Biosciences Inc Stock (JBIO) Company Profile
Firmenname
Jade Biosciences Inc
Sektor
Branche
Telefon
(781) 312-3013
Adresse
221 CRESCENT ST., WALTHAM
Compare JBIO vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
14.12 | 917.07M | 0 | -129.61M | -116.59M | -2.9871 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Eingeleitet | BTIG Research | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-05-07 | Eingeleitet | Wedbush | Outperform |
| 2025-05-05 | Eingeleitet | Stifel | Buy |
| 2025-05-02 | Eingeleitet | TD Cowen | Buy |
| 2024-06-18 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-06-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-06-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-03-25 | Fortgesetzt | Jefferies | Buy |
| 2023-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-12-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-08-16 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-07-26 | Eingeleitet | Cowen | Outperform |
| 2021-07-26 | Eingeleitet | Evercore ISI | Outperform |
| 2021-07-26 | Eingeleitet | Jefferies | Buy |
| 2021-07-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Jade Biosciences Inc Aktie (JBIO) Neueste Nachrichten
Analysts Are Bullish on Top Healthcare Stocks: Jade Biosciences (JBIO), Liquidia Technologies (LQDA) - The Globe and Mail
H.C. Wainwright reiterates Jade Biosciences stock rating at buy - Investing.com India
Jade Biosciences Announces Preclinical Data C - Moomoo
Wedbush reiterates Jade Biosciences stock rating on preclinical data By Investing.com - Investing.com Canada
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in DermatomyositisSlideshow - Seeking Alpha
Stifel reiterates Jade Biosciences stock rating on drug data By Investing.com - Investing.com Nigeria
Jade Biosciences reports preclinical data for dermatomyositis drug - Investing.com
Jade Biosciences reports preclinical data for dermatomyositis drug By Investing.com - Investing.com South Africa
Jade Biosciences advances JADE301 toward Phase 1 trial - TipRanks
Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026 - TradingView
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026 - Yahoo Finance
Jade Biosciences at stifel 2026 virtual immunology and inflammation forum: pipeline push - Investing.com Canada
JBIO: JADE101 leads a robust pipeline with best-in-class data and rapid path to market in IgA nephropathy - TradingView
Jade Biosciences at citigroup summit: fast-track bet on igan By Investing.com - Investing.com India
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 By Investing.com - Investing.com South Africa
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 - Investing.com
Jade Biosciences Company Profile & Introduction - moomoo.com
JADE BIOSCIENCES, INC. : CLEAR STREET RAISES TARGET PRICE TO $48 FROM $25 - moomoo.com
symbol__ Stock Quote Price and Forecast - CNN
Clear Street Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - moomoo.com
LifeSci Capital Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Jade Biosciences to Participate in Upcoming Conferences - Yahoo Finance
Jade Biosciences (JBIO) Slips 1.6% as Shares Test Key Support at $19.97Median Line - dars.gov.et
Jade (JBIO) Financial Update: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Investor Response: Shares End With Little Net Change at the CloseEarnings Season Outlook - dars.gov.et
Bio Ionic Partners with Ulta Beauty on Limited Edition Jade Dream Collection - Yahoo Finance
Jade Biosciences (NASDAQ:JBIO) Shares Gap UpWhat's Next? - MarketBeat
Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027 - Pluang
Jade Biosciences: Duration Is The Real Product (NASDAQ:JBIO) - Seeking Alpha
Jade Biosciences (JBIO) Stock Analysis Report | Financials & Insights - Benzinga España
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Stifel Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
HC Wainwright Analysts Increase Earnings Estimates for JBIO - MarketBeat
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On? - Sahm
Jade Biosciences (JBIO) Advances 2.4% to $22.89 as Buyers Defend Key Support ZoneFlat Correction - vinanet.vn
Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat
Jefferies Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - Moomoo
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX) - theglobeandmail.com
Wedbush Maintains Jade Biosciences(JBIO.US) With Buy Rating, Announces Target Price $47 - Moomoo
A Quick Look at Today's Ratings for Jade Biosciences(JBIO.US), With a Forecast Between $42 to $77 - Moomoo
Jade Biosciences Is Maintained at Buy by BTIG - Moomoo
Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research - MarketBeat
Jade Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
JBIO Q1 2026 Earnings: Wider Loss Highlights Clinical-Stage Investment CycleEarnings Growth Analysis - careplusvn.com
JBIO SWOT Analysis: Financial Challenges and Development Opportu - GuruFocus
Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside - TradingView
Wedbush raises Jade Biosciences price target on pipeline progress By Investing.com - Investing.com Australia
Wedbush raises Jade Biosciences price target on pipeline progress - Investing.com
Jade Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Jade Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Asset Growth - Kalkine Media
Jade Biosciences Q2 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Jade Biosciences' Q2 Loss Narrows - marketscreener.com
Finanzdaten der Jade Biosciences Inc-Aktie (JBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):